A supplemental application for Teclistamab (Tecvayli) received approval from the FDA on March 5, 2026. This approval, identified as BLA 761291 S-18, was granted to Janssen Biotech and specifically pertains to the drug's efficacy.
Background
Teclistamab is a drug developed by Janssen Biotech. The recent supplemental application was categorized under efficacy, indicating a review of additional data supporting the drug's effectiveness.
What this means
This supplemental approval signifies that the FDA has evaluated and accepted further evidence regarding the efficacy of Teclistamab. While specific details of the new efficacy data or expanded indications are not provided in the source information, such approvals typically reinforce or broaden the understanding of a drug's therapeutic benefits.
Source
The information regarding this supplemental approval was obtained from the FDA's website. The details are available on the overview page for BLA 761291, with the event date noted as March 5, 2026, on accessdata.fda.gov.